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Abstract
Introduction: Inherited retinal diseases are the leading cause of sight impairment in
people of working age in England and Wales, and the second commonest in
childhood. Gene therapy offers the potential for benefit.
Sources of data: Pubmed and clinicaltrials.gov.
Areas of agreement: Gene therapy can improve vision in RPE65-associated Leber
Congenital Amaurosis (RPE65-LCA). Potential benefit depends on efficient gene
transfer and is limited by the extent of retinal degeneration.
Areas of controversy: The magnitude of vision improvement from RPE65-LCA gene
therapy is suboptimal, and its durability may be limited by progressive retinal
degeneration.
Growing points: The safety and potential benefit of gene therapy for inherited and
acquired retinal diseases is being explored in a rapidly expanding number of trials.
Areas timely for developing research: Developments in vector design and delivery
will enable greater efficiency and safety of gene transfer. Optimisation of trial design
will accelerate reliable assessment of outcomes.
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Introduction
The retina is a highly specialised, multi-layered tissue that includes a layer of light-
sensitive cone- and rod-photoreceptor cells, which initiate neuronal signalling in
response to light stimulation by means of a highly sophisticated cascade of
enzymatic reactions (phototransduction). The photoreceptor cells are supported by
a monolayer of pigmented cells, the retinal pigment epithelium (RPE), which
performs many key processes including the regeneration of visual pigment (the
visual cycle) which is bleached following light exposure. Diseases of the retina,
including age-related macular degeneration, inherited retinal diseases (IRDs),
diabetic retinopathy, and vascular occlusion represent the commonest cause of
severe sight impairment in the developed world. Inherited retinal diseases are the
leading cause of blindness in people of working age in England and Wales, and the
second commonest cause in children.1 Defects in genes encoding proteins involved
in the phototransduction cascade or the visual cycle account for a large proportion
of IRDs.
Gene therapy offers an opportunity to improve outcomes of inherited monogenic
disorders of the retina. In its simplest and commonest form, gene ‘supplementation’
therapy compensates for a genetic deficiency, resulting from loss-of-function
mutations in the endogenous gene, by provision of the normal gene to the cells in
which it is required.2 The therapeutic gene, typically delivered using a viral vector, is
utilised by the transcriptional machinery of the target cell to generate the normal
gene product that is otherwise lacking. Alternative gene therapy techniques aim to
Retinal Gene Therapy: A Review 4
suppress the undesirable expression of a harmful protein product resulting from
gain-of-function mutations, with or without simultaneous provision of the normal
gene.3 In addition, gene editing strategies to correct harmful mutations in
endogenous genes, and anti-sense oligonucleotide mediated exon skipping to
mitigate their impact, are also being investigated. The first gene therapy product
approved by the European Medicines Agency was Glybera, for the treatment of
lipoprotein lipase deficiency.4
Here we describe the key strategies of ocular gene therapy and focus on its
application to disease of the retina, with emphasis on experimental therapies in
clinical trials. Figure 1 is a schematic diagram of the location of genes in cells of the
outer retina targeted in current gene therapy trials. Similar techniques have been
used in clinical gene therapy trials targeting other single-gene diseases, including
primary immune deficiencies, haemoglobinopathies, haemophilia B, neurological
diseases, cancer immunotherapies.4
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Figure 1: Schematic diagram showing the outer retina and the cellular location of
poducts of the genes targeted by current gene therapy trials (red) and the genes
explored for future trials (black).
Gene Therapy and the Eye
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The retina has specific advantages as a target organ for gene therapy. The optical
transparency of the ocular media provides accessibility for microsurgical delivery of
vector suspension to the retina under direct visualisation, and for high-resolution
imaging at a cellular level of definition for targeting of intervention and assessment
of its impact. Vector suspension can be targeted to the retina with minimal systemic
dissemination owing to the contained nature and compartmentalisation of the
intraocular tissues. The intraocular environment provides the retina with a degree of
immune privilege, which limits immune responses that could adversely affect retinal
function and limit expression of the therapeutic gene. Since inherited retinal disease
typically causes bilateral disease with significant symmetry, the untreated
contralateral eye offers a valuable control for natural history, learning effects and
intra-individual variability in performance.
For gene transfer to retinal cells, most clinical applications currently employ
recombinant adeno-associated virus (AAV) or lentivirus vectors. AAV is a small, non-
pathogenic single stranded DNA virus widely used for gene delivery in IRDs. AAV
vectors can mediate efficient and sustained transduction of photoreceptor cells,
retinal pigment epithelium, and ganglion cells. First generation AAV2 vectors are
limited by relatively slow onset of expression and small capacity (4.7 kB)5. However,
the isolation of alternative serotypes and the development of self-complementary
vectors and novel variants, by rational design and/or directed evolution, have
provided a broad range of alternatives with more rapid expression and cell
tropisms.6,7 Measures to address the limited capacity include dual AAV vector
strategies in which a large gene delivered in component parts by AAV is
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reconstituted by splicing.8 Since lentiviral vectors have substantially greater capacity
(approximately 8 kB) than AAV, they can naturally accommodate larger genes.
Lentiviral vectors mediate efficient transduction that is typically limited to retinal
pigment epithelial cells but one type of lentiviral vector, derived from the equine
infectious anaemia virus, mediates variable transgene expression in photoreceptor
cells.9 Vector capacity is a fundamentally important issue given that the most
common genes causing IRD are large, including ABCA4 (Stargardt Disease) and
USH2A (syndromic and non-syndromic Retinitis Pigmentosa).
Intraocular Administration
Since defects in genes involved in phototransduction or the visual cycle account for
many IRDs, photoreceptors and retinal pigment epithelial cells are important target
populations for gene therapy. Viral vectors deliver genes to these cells efficiently
when the vector suspension is placed in direct contact with the cells in the outer
retina. This is typically achieved by injecting the vector suspension between the
retinal pigment epithelium and the overlying photoreceptor cell layer. Injection into
this potential subretinal space is typically performed using a fine cannula that is
advanced through the sclera anteriorly, across the vitreous cavity and through the
inner retina (Figure 2a). Injection into this site generates a bleb of vector suspension
that temporarily separates the neurosensory retina from the underlying retinal
pigment epithelium, before it is absorbed over a period of hours or days. Injection of
vector suspension into the vitreous cavity (Figure 2b) can result in gene delivery to
cells of the inner retina, including ganglion cells. Although intravitreal vector is
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technically simpler than subretinal injection, anatomical barriers prevent efficient
gene delivery to the outer retina and this route of administration may be more
immunogenic than subretinal injection.10 Compromise of inner retinal integrity, in
conditions such as X-linked Retinoschisis, may enable enhanced access of intravitreal
vector suspensions to the inner retina.11 Delivery of vector suspensions into the
suprachoroidal potential space (between the sclera and choroid) may enable
targeting of the choroid, for conditions such as age-related macular degeneration
and idiopathic polypoidal choroidal vasculopathy.12
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Figure 2: Schematic diagram identifying ocular structures and location of (A)
subretinal injection and (B) intravitreal injection.
Current Gene Therapy Clinical Trials
RPE65
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Leber Congenital Amaurosis (LCA), first described by Theodore Leber in 1869, is a
group of recessively inherited infantile-onset rod-cone dystrophies. The prevalence
ranges from 1 in 33,000 to 1 in 81,000.13 LCA accounts globally for 5% of IRDs and
20% of children attending specialist schools for students with sight impairment.14
Mutation of one of several genes, including RPE65, causes impaired vision from
birth/early infancy and typically progresses to severe sight impairment. Figure 3
demonstrates the appearance of the retina in RPE65-associated Leber congenital
amaurosis. RPE65 is expressed in the retinal pigment epithelium and encodes a 65-
kD protein that is a key component of the visual cycle, a biochemical pathway that
regenerates the visual pigment after exposure to light. 15,16 A lack of functional
RPE65 results in deficiency of 11-cis retinal such that rod photoreceptor cells are
unable to respond to light.17 Cone photoreceptor cells have access to 11-cis–
retinaldehyde chromophore through an alternative pathway that does not depend
on retinal pigment epithelium–derived RPE65 thus allowing cone-mediated vision in
children.18 However, progressive degeneration of cone photoreceptor cells
ultimately results in the loss of cone-mediated vision. Gene-replacement therapy can
improve visual function in rodent models of RPE65-LCA, and in the Swedish Briard
dog, which has a naturally occurring mutation in RPE65.19 The treated eyes of dogs
showed improved responses on electroretinography, pupillometry and flash-evoked
cortical potentials in the dark-adapted state, with improvements sustained for as
long as 10 years.19
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Figure 3: Colour fundus photographs of (A) a patient with RPE65-associated Leber
congenital amaurosis and (B) an unaffected individual for comparison. (A) shows
peripheral RPE atrophy with a tessellated appearance to the fundus owing to the
choroidal vasculature, with central preservation of retinal structure.
The first trial of ocular gene therapy for humans with RPE65-LCA was reported in
200820. Several phase I/II trials have provided proof of principle that subretinal
injection of a recombinant AAV 2/2 vector containing the RPE65 cDNA can improve
retinal function and vision.20-23 The findings of a subsequent open-label randomised
controlled trial confirm benefit at 1 year to night vision, as indicated by improved
performance in a test of vision-guided mobility in low luminance, and to visual
fields.24 In 2017 the US FDA approved voretingene neparvovec (Luxturna, Spark
Therapeutics Inc) for the treatment of RPE65-associated LCA. Longer term findings
indicate that, despite improved function of surviving retina, the durability of benefit
can be limited by progressive retinal degeneration.23,25-27 To investigate the
hypothesis that greater provision of RPE65 will provide more durable, robust benefit,
the impact of a more efficient optimised AAV 2/5 vector is being investigated.28
Figure 4 illustrates one example of improved retinal sensitivity in RPE65-associated
LCA following intervention gene therapy, as demonstrated by advanced hill of vision
modelling.29
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Figure 4: An oblique topographical view of the central hill of vision, produced by
Visual Field Modelling and Analysis (VFMA, Office of Technology Transfer and
Business Development [OHSU], Portland, Oregon, USA)29 in a subject (A) prior to and
(B) following gene therapy intervention (A) shows residual central visual field prior to
intervention, in comparison to (B) which demonstrates increased retinal sensitivity
and therefore a larger and taller hill of vision at one year post-intervention.
CNGA3, CNGB3
Achromatopsia (ACHM) is a recessively inherited disorder of cone photoreceptor
function affecting approximately 1 in 30,000 people. The condition causes severe
impairment of sight from birth with poor visual acuity, absent or markedly reduced
colour vision, disabling photophobia and pendular nystagmus.30 ACHM can be
caused by mutations in any one of at least 6 genes including CNGA3 and CNGB3,
which encode the alpha and beta subunits respectively of the cone photoreceptor
cyclic nucleotide gated channels, and account for the majority of people affected.30
Structural preservation of individual cone photoreceptors can be determined in
affected humans by adaptive optics scanning laser ophthalmoscopy (AO-SLO)30, to
evaluate their potential to benefit from gene therapy and determine the impact of
intervention. AAV-mediated gene replacement therapy can improve cone function in
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rodent models of both CNGA3-ACHM31 and CNGB3-ACHM32, and in canine models of
CNGB3-ACHM.30 Early phase clinical trials of gene therapy for both CNGA3-ACHM
and CNGB3-ACHM will determine the extent to which this approach might benefit
visual acuity, colour discrimination, photophobia and nystagmus in affected humans.
(NCT02599922, NCT03001310, NCT02610582, NCT02935517).
RPGR
Retinitis Pigmentosa (RP) is a term used to describe the clinical phenotype of rod-
cone retinal degenerations, which can be caused by defects in a wide range of genes
that collectively affect 1 in 2-3,000 people. X-linked RP (XLRP) accounts for 15-25% of
RP and is particularly severe, with onset in childhood and progressively severe sight
impairment during early adulthood. Seventy to eighty percent of XLRP is caused by
sequence variants in the RPGR gene, which encodes the retinitis pigmentosa GTPase
regulator.33 In both rodent and canine models of the condition, AAV-mediated gene
supplementation using truncated or codon-optimised constructs to improve
transgene stability have slowed retinal degeneration.34,35 Phase I/II trials of AAV-
mediated gene therapy in affected humans are ongoing (NCT03116113,
NCT03252847).
CHM
Choroideraemia is an X-linked recessive disorder, characterised by night-blindness in
childhood, with gradually progressive constriction of peripheral vision leading to
impairment of central vision in later life. Choroideremia is caused by sequence
variants in the 1.9kb CHM gene that encodes Rab escort protein 1 (REP1), which is
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required for intracellular vesicular transport.36 In a phase I/II clinical trial, subretinal
injection of AAV2 vector expressing REP1 is reported to be well tolerated and
associated with improved function in some instances.37,5. Long-term follow up will be
needed to determine whether gene therapy can protect against progressive
constriction of visual fields owing to retinal degeneration. (NCT01461213,
NCT02553135, NCT02671539, NCT02077361).
MERTK
Defects in the gene encoding MERTK, a receptor tyrosine kinase essential for
removal of waste material from photoreceptors, result in accumulation of debris and
progressive rod-cone retinal degeneration (retinitis pigmentosa).38 39 In a rodent
model of the disease, gene replacement therapy by subretinal administration of
AAV2 vectors encoding Mertk can improve the outcome.40,41 In a phase I/II clinical
trial, an AAV2- MERTK vector was well tolerated in affected humans with a
suggestion of temporary benefit in some participants.42
RS1
X-Linked Retinoschisis (XLRS) causes impairment of sight in childhood, with variable
progression in later adulthood. The prevalence is estimated to be 1 in 10,000 men.
Associated features include strabismus, refractive error, and anisometropia. Gene
defects in RS1, which encodes retinoschisin, impair adhesion and transmission
between photoreceptor and bipolar cells, leading to schisis of the macula and retinal
dysfunction. 50% of patients also have peripheral retinoschisis which presents a risk
of associated retinal detachment and vitreous haemorrhage. Intravitreal delivery of
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AAV2 or AAV8 vectors encoding RS1 improves the outcome in Rs1-deficient mice,
and appears safe in rabbits.11,43,44 Phase I/II dose-escalation clinical trials of
intravitreal gene replacement of RS1 using AAV2 and AAV8 vectors are on-going
(NCT02317887, NCT02416622).
Candidate genes for future clinical trials
AIPL1
Aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1) is a molecular
chaperone of phosphodiesterase 6, which mediates rod photoreceptor specific
phototransduction. Mutations in AIPL1 cause a particularly severe, rapidly
progressive form of LCA (AIPL1-LCA). Affected individuals present with severe sight
impairment from birth and rapid retinal degeneration. Although the natural history
is very poor, some preservation of retinal structure during infancy in humans45
indicates a window of opportunity for intervention by gene replacement therapy,
with the potential for benefit demonstrated experimentally in a rodent model.46,47
GUCY2D
Retinal guanylate cyclase-1 is essential in photoreceptor cells for timely recovery
from photoexcitation. Mutations in the GUCY2D gene account for 10-20% of LCA and
photoreceptor architecture is relatively well preserved.48 Improved retinal function
following gene replacement therapy using AAV5 and AAV2/8 and AAV8 based gene
therapy in mouse models indicates that affected humans may benefit.48,49
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CEP290
CEP290 encodes a centrosomal protein involved in trafficking through the
connecting cilia of photoreceptor cells. Mutations in CEP290 account for 30% of LCA.
The size of the full-length gene exceeds the capacity of AAV vectors for a gene
replacement strategy. However, the most common disease-causing variant, the
intronic variant c.2991+1655 A>G, creates a cryptic splice donor site and premature
stop codon that may be addressed by alternative strategies such as anti-sense
oligonucleotides or CRISPR/Cas9-mediated gene editing.50
ABCA4
Stargardt disease (STGD1) results from mutations in the photoreceptor-specific
flippase ABCA4, leading to intracellular accumulation of a toxic retinoid, and
degeneration of the outer retina. STGD1 is the most common inherited macular
degeneration, with an incidence of 1 in 10,00051, causing progressively severe
impairment of sight from early childhood or adulthood. The full-length ABCA4 gene
(6.8kb) exceeds the carrying capacity of AAV vectors. Alternative strategies for gene
replacement include the use of oversized AAV5 vectors52, trans-splicing and hybrid
AAV2 dual vector systems8. The use of a lentiviral vector based on Equine Infectious
Anaemia Virus (EIAV) is reported to improve the outcome in a rodent model of the
condition53 and to be well-tolerated in non-human primates.54 A phase I/II dose
escalation clinical trial of EIAV-ABCA4 vector is on-going (NCT01367444).
MYO7A
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Usher Syndrome is a recessively inherited condition characterised by impairment of
sensorineural hearing and progressive impairment of sight owing to rod-cone
degeneration. It is clinically and genetically heterogeneous, and is associated with
defects in as many as 10 genes.55 Usher syndrome type 1B is caused by defects in the
myosin VIIa (MYO7A) gene, resulting in abnormal accumulation of opsin in the cilia
of photoreceptor cells. Like ABCA4, the large size of the MYO7A (8.1kb) gene52
exceeds the carrying capacity of conventional AAV2/2 vectors. Alternative strategies
include the use of dual vectors8,56 to deliver gene fragments that are reassembled by
homologous recombination following transduction, oversized AAV5 vectors52, and
lentiviral vectors57,58. Subretinal injection of EIAV-MYO7A is well tolerated in non-
human primates, and the potential for benefit to vision in humans is being explored
in an on-going phase I/II clinical trial (NCT01505062).58
RHO
Many disease-causing sequence variants in RHO, which encodes the rod-
photoreceptor pigment rhodopsin, have dominant negative effects in which the
protein interferes with essential cell functions leading to variably severe rod-cone
degeneration 59. More than 150 such mutations in RHO have been identified,
accounting for 20-30 % of autosomal dominant retinitis pigmentosa.60 Strategies to
suppress expression of the disease allele specifically are currently unfeasible owing
to the substantial mutational heterogeneity. One alternative strategy is to suppress
both the mutant and wild-type allele non-specifically, and simultaneously to provide
a replacement gene that encodes the wild-type protein which has been modified to
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resist suppression.61 This approach can improve the outcome in a rodent model but
has yet to be explored in affected humans.
Age-related macular degeneration (AMD)
Age related macular degeneration (AMD) is the leading cause of vision loss in
individuals over the age of 60. AMD can be classified as neovascular (wet) or dry.
Impairment of sight from neovascular AMD and proliferative diabetic retinopathy is
a direct consequence of pathological neovascularisation which is driven strongly
through the up-regulation of vascular endothelial growth factor (VEGF.) The use of
therapeutic anti-VEGF antibodies has resulted in substantially improved outcomes
for these conditions, but sustained benefit requires regularly repeated intraocular
injections. Vector-mediated gene expression of angiostatic proteins offers the
opportunity to achieve sustained intraocular delivery following a single injection.
Subretinal injection of a rAAV 2/2 vector expressing the soluble VEGF receptor sFlt-1
appears to be well tolerated in humans with neovascular AMD, though a larger study
will be needed to determine benefit (NCT0149805).62,63 Intravitreal injection of an
AAV2 vector expressing sFlt-1 in advanced neovascular AMD was followed by
improved structure in a minority.64 Intraocular expression of sFlt-1 was sustained but
variable and possibly limited by antibody-mediated immune responses to AAV2, with
clinical signs of inflammation evident in some instances (NCT01024998).
Subretinal delivery of RetinostatTM, a non-replicating EIAV vector containing genes
encoding the angiostatic proteins Endostatin and Angiostatin, appears safe in
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rodent65 and non-human primate models 66. In humans with neovascular AMD,
subretinal injection of RetinostatTM results in sustained intraocular transgene
expression, and appears well tolerated (NCT01301443.)67
Dry AMD is characterised by dysfunction and degeneration of retinal pigment
epithelial cells and formation of deposits called drusen. Multiple theories have been
proposed to explain the underlying pathogenies including a predominantly
inflammatory aetiology, with an over active complement cascade resulting in the
accumulation of a membrane attack complex (MAC) leading to cell damage and
death having been implicated.68 The protein CD59 is seen in normal human cells to
block MAC.69 A gene therapy product to increase expression of a soluble form of
CD59 (sCD59) is currently being investigated (NCT03144999).
The Future
The benefits of gene therapy for LCA-RPE65 have led to approval by the FD of the
first gene therapy for ocular disease, and to a rapid expansion in clinical trials
exploring the safety and potential benefit of gene therapy for other inherited and
acquired retinal diseases. The results will help define for each condition the potential
window of opportunity for effective intervention. Further developments in vector
design and delivery will enable greater efficiency and safety of gene transfer. Rapid
reliable assessment of outcomes will be accelerated by optimisation of clinical trial
design.
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Table 1
Disease Gene Gene Function Vector Mode Phase CurrentStatus
Clinical Trials
ID Sponsor Location
LCA-2 RPE65 Retinoid cycle AAV2/2 Subretinal III Ongoing NCT00999609NCT01208389
Spark
Therapeutics UK
LCA-2 RPE65 Retinoid cycle AAV2/2 Subretinal I Ongoing NCT00516477 SparkTherapeutics USA
LCA-2 RPE65 Retinoid cycle AAV2/5 Subretinal I/II Ongoing NCT02781480NCT02946879
MeiraGTx UK II
Ltd UK
















LCA-2 RPE65 Retinoid cycle AAV2/2 Subretinal I/II Completed NCT00643747 UniversityCollege London UK
























Choroideraemia REP1 Intracellulartrafficking AAV2 Subretinal II Ongoing NCT02553135
University of
Miami USA
Choroideraemia REP1 Intracellulartrafficking AAV2 Subretinal II Ongoing NCT02671539 STZ Eyetrial Germany















Choroideraemia CHM Intracellulartrafficking AAV2 Subretinal I/II Ongoing NCT02341807
Spark
Therapeutics USA






X-Linked RP RPGR Intracellulartransport AAV8 Subretinal I/II Ongoing NCT03116113 NightstaRx UK
X-Linked RP RPGR Intracellulartransport AAV2/5 Subretinal I/II Ongoing NCT03252847
MeiraGTx UK II
Ltd UK





Achromatopsia CNGB3 Phototransduction AAV2/8 Subretinal I/II Ongoing NCT03001310 MeiraGTx UK II UK
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cascade Ltd

























Neovascular-AMD sFLT01 Anti-angiogenesis AAV2 Intravitreal I Ongoing NCT01024998 Sanofi USA
Neovascular-AMD AntiVEGFfab Anti-angiogenesis AAV8 Subretinal I Ongoing NCT03066258 Regenxbio USA
Neovascular-AMD sFLT01 Anti-angiogenesis AAV2 Subretinal I/II Completed NCT01494805 Lions EyeInstitute Australia
Neovascular-AMD Endostatin/Angiostatin Anti-angiogenesis EIAV Subretinal I Completed NCT01301443
Oxford
BioMedica USA






channels AAV2 Intravitreal I/II Ongoing NCT02556736 Allergan USA
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Table 1: Clinical trials of retinal gene therapy (LCA: Leber Congenital Amaurosis, RP: Retinitis Pigmentosa.) *RNA antisense oligonucleotides are
administered without a vector.
